
KelSie Biotech develops high bioavailability delivery methods, including dry powder inhalable products for easy dosage.
KelSie Biotech, founded with a mission to revolutionize drug delivery systems, focuses on developing high bioavailability methods for sensitive Active Pharmaceutical Ingredients (APIs). The company specializes in creating dry powder inhalable products using its patented Carbon-Dioxide Assisted Nebulization Bubble Drying (CAN-BD) process, as well as sublingual wafers. These innovations aim to make daily dosages more accessible and effective for patients, positioning KelSie Biotech at the forefront of pharmaceutical delivery technology.
Notable figures associated with KelSie Biotech include experienced leaders in the biotech and pharmaceutical industries who have driven the company's technological advancements. The company has achieved significant milestones, including the successful implementation of its CAN-BD technology, which has garnered attention for its potential to improve drug efficacy and patient compliance. KelSie Biotech's impact is evident in its contributions to making complex drug formulations more user-friendly and effective, thereby enhancing patient outcomes and setting new standards in the biotech field.

Nob Hill Therapeutics

Syntis Bio
syntis.bio

Qnovia
qnovia.com

Pure Scientific Technologies

Surf Bio
surf.bio

BioSapien
biosapien.com

Transpire Bio
transpirebio.com

Elektrofi
elektrofi.com
Control Delivery Systems

Souvie Biodelivery

Respira Therapeutics

Kinaset Therapeutics
kinasettx.com

Ensysce Biosciences
ensysce.com

BioKier
biokier.com

TFF Pharmaceuticals
tffpharma.com
Companies similar to KelSie Biotech include Nob Hill Therapeutics, Syntis Bio, Qnovia and Pure Scientific Technologies.
KelSie Biotech was founded in 2017.
KelSie Biotech's headquarters is located in Englewood, CO, US.
KelSie Biotech's most recent funding round was for $1.3M (USD) in April 2021.
As of Apr 2, 2021, KelSie Biotech has raised a total of $1.3M (USD).
KelSie Biotech has 6 employees as of Feb 5, 2024.